07/03/2016

ESTEVE’S R&D, AGAIN RATED ’EXCELLENT’ BY PROFARMA PLAN

The Profarma Plan (Plan to Promote Scientific Research, Technological Development and Innovation in the Pharmaceutical Industry) of the Ministry of Industry, Energy and Tourism has one more year rated ESTEVE's R&D activities as 'excellent'. This is the 29th consecutive time that our laboratory receives this seal of quality, ever since the launch of Profarma in 1986.

ESTEVE is classified in Group A of the Proforma Plan (2013-2016), which includes pharmaceutical companies with significant research activities that have their own production center or basic or preclinical R&D.

Innovation and internationalization are two strategic axes at ESTEVE, a company that invests 63 million Euros a year in research and has a workforce of 2,279 professionals, 10% of which devoted exclusively to R&D activities. This firm commitment and effort have again resulted in the annual renovation of the maximum rating granted by Profarma, an official seal of quality that fosters R&D in the pharmaceutical sector.

You can follow ESTEVE on Twitter at this link: twitter.com/esteve_news.

Related Information

Last news

  • THE PROGRAM ’PLAN PROFARMA’ HAS ONCE AGAIN QUALIFIED ESTEVE’S R&D&I AS ’’EXCELLENT’’

    Once again, ESTEVE's research activity has received the qualification ''Excellent'' in the Program 'Plan Profarma' (Program for Fostering Scientific Research, Technological Development and Innovation ...

    read more
  • PENSA PHARMA HAS BEEN AWARDED A PRIZE FOR ITS BEST DEVELOPMENT AND COMMERCIALIZATION OF GENERIC MEDICINES

    Pensa Pharma (PENSA), a company of the ESTEVE Group specialized in generic medicines, has been awarded a prize at the II edition of La Razón Comunidad Valenciana Awards. Specifically, PENSA has receiv...

    read more
  • ESTEVE APPOINTS THOMAS B. RIISAGER AS CHIEF CORPORATE STRATEGY & BUSINESS DEVELOPMENT OFFICER

    ESTEVE has announced today the appointment of Thomas B Riisager as Chief Corporate Strategy & Business Development Officer, to be heading Corporate Strategy & Business Development for the pharmaceutic...

    read more

Follow us at

This Website uses its own and third-party cookies to improve our services and analyse the user's browsing habits. If you continue browsing, we will consider you to have accepted their use. You can find more information by visiting our Cookies policy.